Status:

UNKNOWN

Untargeted Metabolomics for Primary Aldosteronism

Lead Sponsor:

Liverpool University Hospitals NHS Foundation Trust

Conditions:

Primary Aldosteronism

Eligibility:

All Genders

18-120 years

Brief Summary

Primary aldosteronism (PA) is a common and likely under-diagnosed cause of secondary hypertension with associated cardiovascular morbidity and mortality. Current diagnosis comprises screening, confirm...

Detailed Description

Participant Recruitment * Suitable participants will be identified by members of their care teams, for whom screening, confirmatory testing and lateralisation will be / have been completed at LUHFT. ...

Eligibility Criteria

Inclusion

  • Screening for PA to be performed in people with:
  • sustained blood pressure (BP) above 150/100 mm Hg on each of three measurements obtained on different days, with hypertension (BP \>140/90 mm Hg) resistant to three conventional antihypertensive drugs (including a diuretic), or controlled BP (\<140/90 mm Hg) on four or more antihypertensive drugs.
  • hypertension and spontaneous or diuretic-induced hypokalaemia.
  • hypertension and adrenal incidentaloma.
  • hypertension and sleep apnoea.
  • hypertension and a family history of early onset hypertension or cerebrovascular accident at a young age (\<40 years).
  • all hypertensive first-degree relatives of people with PA.
  • Subset of people being screened for PA who are eligible for inclusion in this study:
  • 18 years of age or older.
  • People under the care of LUHFT.
  • Able to give informed consent.
  • Having lithium heparin plasma samples collected as part of their routine care.

Exclusion

  • Under 18 years of age.
  • Unable to give informed consent.
  • Insufficient clinical/biochemical/radiological/histological information to accurately assign patients to PA or non-PA subsets.

Key Trial Info

Start Date :

January 19 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

January 19 2025

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT06076473

Start Date

January 19 2023

End Date

January 19 2025

Last Update

February 15 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Liverpool University Hospitals NHS Foundation Trust

Liverpool, Merseyside, United Kingdom, L9 7AL

Untargeted Metabolomics for Primary Aldosteronism | DecenTrialz